Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gordon R Greenberg

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Inflammatory Bowel Diseases|August 5, 2004
Antibiotics should be used as first-line therapy for Crohn's diseaseGordon R Greenberg
The American Journal of Gastroenterology|May 11, 2002
Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapyMaria Cino, Gordon R Greenberg
American Journal of Physiology. Endocrinology and Metabolism|July 12, 2002
Somatostatin-28 regulates GLP-1 secretion via somatostatin receptor subtype 5 in rat intestinal culturesConnie Chisholm, Gordon R Greenberg
Inflammatory Bowel Diseases|October 9, 2004
Comparison of a disease activity index and patients' self-reported symptom severity in ulcerative colitisRobert G Maunder, Gordon R Greenberg
The American Journal of Gastroenterology|September 1, 2005
Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's diseaseMichael Bernstein, Sue Irwin, Gordon R Greenberg
Gastroenterology|June 10, 2004
Successful treatment of cap polyposis with infliximabIan D Bookman, Mark S Redston, Gordon R Greenberg
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 26, 2006
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's diseaseElana A Maser, Renata Villela, Mark S Silverberg, et al.
The American Journal of Gastroenterology|December 23, 2003
Clinical and radiological responses after infliximab treatment for perianal fistulizing Crohn's diseaseImran Rasul, Stephanie R Wilson, Helen MacRae, et al.
Inflammatory Bowel Diseases|September 29, 2005
Attachment insecurity moderates the relationship between disease activity and depressive symptoms in ulcerative colitisRobert G Maunder, William J Lancee, Jonathan J Hunter, et al.
The American Journal of Gastroenterology|August 10, 2005
Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trialsWilliam J Sandborn, Robert Löfberg, Brian G Feagan, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Inflammatory Bowel Diseases|August 5, 2004
Antibiotics should be used as first-line therapy for Crohn's diseaseGordon R Greenberg
The American Journal of Gastroenterology|May 11, 2002
Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapyMaria Cino, Gordon R Greenberg
American Journal of Physiology. Endocrinology and Metabolism|July 12, 2002
Somatostatin-28 regulates GLP-1 secretion via somatostatin receptor subtype 5 in rat intestinal culturesConnie Chisholm, Gordon R Greenberg
Inflammatory Bowel Diseases|October 9, 2004
Comparison of a disease activity index and patients' self-reported symptom severity in ulcerative colitisRobert G Maunder, Gordon R Greenberg
The American Journal of Gastroenterology|September 1, 2005
Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's diseaseMichael Bernstein, Sue Irwin, Gordon R Greenberg
Gastroenterology|June 10, 2004
Successful treatment of cap polyposis with infliximabIan D Bookman, Mark S Redston, Gordon R Greenberg
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 26, 2006
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's diseaseElana A Maser, Renata Villela, Mark S Silverberg, et al.
The American Journal of Gastroenterology|December 23, 2003
Clinical and radiological responses after infliximab treatment for perianal fistulizing Crohn's diseaseImran Rasul, Stephanie R Wilson, Helen MacRae, et al.
Inflammatory Bowel Diseases|September 29, 2005
Attachment insecurity moderates the relationship between disease activity and depressive symptoms in ulcerative colitisRobert G Maunder, William J Lancee, Jonathan J Hunter, et al.
The American Journal of Gastroenterology|August 10, 2005
Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trialsWilliam J Sandborn, Robert Löfberg, Brian G Feagan, et al.
Pageof 4